U S Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 4.99 Cr
as on 24-10-2024
- Paid Up Capital ₹ 1.24 Cr
as on 24-10-2024
- Company Age 21 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.00 Cr
as on 24-10-2024
- Satisfied Charges ₹ 15.43 Cr
as on 24-10-2024
- Revenue 32.41%
(FY 2023)
- Profit 143.65%
(FY 2023)
- Ebitda 157.11%
(FY 2023)
- Net Worth 31.38%
(FY 2023)
- Total Assets 12.09%
(FY 2023)
About U S Pharma (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.99 Cr and a paid-up capital of Rs 1.24 Cr.
The company currently has active open charges totaling ₹9.00 Cr. The company has closed loans amounting to ₹15.43 Cr, as per Ministry of Corporate Affairs (MCA) records.
Tapan Sanghvi and Mansi Sanghvi serve as directors at the Company.
- CIN/LLPIN
U24230MH2003PTC140514
- Company No.
140514
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 May 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at U S Pharma (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tapan Sanghvi  | Director | 12-Dec-2014 | Current |
| Mansi Sanghvi | Director | 30-Sep-2020 | Current |
Financial Performance of U S Pharma (India).
U S Pharma (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 32.41% increase. The company also saw a substantial improvement in profitability, with a 143.65% increase in profit. The company's net worth Soared by an impressive increase of 31.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of U S Pharma (India)?
In 2023, U S Pharma (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Oceanic Laboratories Private LimitedActive 33 years 8 monthsTapan Sanghvi and Mansi Sanghvi are mutual person
Euro Medicare Laboratories LlpActive 6 years 6 monthsTapan Sanghvi and Mansi Sanghvi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Oct 2022 | ₹7.00 Cr | Open |
Sidbi Creation Date: 10 Aug 2021 | ₹2.00 Cr | Open |
Others Creation Date: 19 Jan 2022 | ₹8.50 Cr | Satisfied |
How Many Employees Work at U S Pharma (India)?
Unlock and access historical data on people associated with U S Pharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of U S Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped U S Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
